Kazan hosts the traditional annual international conference «Actual problems of ensuring the quality of drug and medical care.» Among the topics discussed are the legislative aspects of the availability of medicines and technologies for children, the possibilities of financing medical care for patients with rare diseases at the federal and regional levels, the pharmaceutical market in a changing environment, the economic realities the life of a pharmacy, and much more.
Chairman of the Public Council under the Federal service for Surveillance in Healthcare (Roszdravnadzor), General Director of the ARPM Victor Dmitriev moderated the round table «Import substitution: opportunities now and in the future.» Starting the session, he dwelled on the problems that stand in the way of successful import substitution, noting among them the complication of supply chains, the need for the industry to switch to alternative packaging materials and printing raw materials, and the instability of work and incorrect information in the Drug Movement Monitoring (DMM) system, and the imperfection of the legislative framework, as a result of which the already adopted legal acts “do not work”, and the bureaucratic obstacles that the pharmaceutical industry has to face. «There are many questions, but we see ways to solve them,» said the head of the ARPM. “The industry is doing everything it can to keep facilities going.”
Alexander Bykov, director of healthcare economics at R-Pharm, supported his colleague, noting that law enforcement and non-financial support measures are extremely important for the industry. “It is necessary to create “fast tracks” so that Russian innovative products receive appropriate support,” he added.
The topic of public procurement was also raised at the round table. Ekaterina Zadonskaya, General Director of Cursor Marketing, presented a comparative analysis showing that the share of failed auctions in 2022 increased compared to 2021. At the same time, Ekaterina called the main reason for the cancellation of the auction the situation when not a single application was submitted. This topic aroused great interest and discussion in the hall. Taking the floor, Victor Dmitriev pointed out that one of the main problems of the pharmaceutical industry is the multi-headedness of the regulator and called on everyone to put the interests of patients at the forefront.